evaluation
71 36 31
20 12 12
10 5 5
89.8 %
98.1%
80.0%
70.4% 94.4% 100.0%
every subscheme, at least 70% of the participants
were successful according to the pre-defined
criteria. For the EGFR and ROS1 FISH subschemes,
the percentage of successful participants was the
lowest, in concordance with the higher number of
laboratories analysing at least one of the samples
incorrectly. On sample and laboratory levels, more
technical failures were observed for ROS1 compared
with other markers.
Although reporting scores were all above
80% (Table 1), only 43–52% of the participants
were able to correctly include the clinical
interpretation of the analysis result, depending
on the marker of interest.
Discussion
Our results demonstrate decreased error and
technical failure rates